Abstract Sporadic Alzheimer disease (sAD) is associated with impairment of insulin receptor (IR) signalling in the brain. Rats used to model sAD develop insulin-resistant brain state following intracerebroventricular treatment with a betacytotoxic drug streptozotocin (STZ-icv). Brain IR signalling has been explored usually at only one time point in periods B3 months after the STZ-icv administration. We have investigated insulin signalling in the rat hippocampus at five time points in periods B9 months after STZ-icv treatment. Male Wistar rats were given vehicle (control)-or STZ (3 mg/kg)-icv injection and killed 0.5, 1, 3, 6 and 9 months afterwards. Insulin-1 (Ins-1), IR, phospho-and total (p/t)-glycogen synthase kinase 3-b (GSK-3b), p/t-tau and insulin degrading enzyme (IDE) mRNA and/or protein were measured. Acute upregulation of tau and IR mRNA (p \ 0.05) was followed by a pronounced downregulation of Ins-1, IR and IDE mRNA (p \ 0.05) in the course of time. Acute decrement in p/t-tau and p/t-GSK-3b ratios (p \ 0.05) was followed by increment in both ratios (3-6 months, p \ 0.05) after which p/t-tau ratio demonstrated a steep rise and p/t-GSK-3b ratio a steep fall up to 9 months (p \ 0.05). Acute decline in IDE and IR expression (p \ 0.05) was followed by a slow progression of the former and a slow recovery of the latter in 3-9 months. Results indicate a biphasic pattern in time dependency of onset and progression of changes in brain insulin signalling of STZ-icv model (partly reversible acute toxicity and chronic AD-like changes) which should be considered when using this model as a tool in translational sAD research.
Introduction
Late onset Alzheimer disease (sAD) is a chronic heterogeneous disease of aging characterized by a progressive cognitive decline (Nelson et al. 2009; Blennow et al. 2006) . Neuropathologically, sAD is characterized by a loss of neurons and synapses, especially in hippocampus and cortex, the extracellular accumulation of amyloid-b (Ab) peptide plaques, and the presence of intracellular neurofibrillary tangles (NFT) composed of hyperphosphorylated tau protein (Grundke-Iqbal et al. 1986; Goedert and Spillantini 2006) .
A growing body of evidence has indicated that insulin homeostasis in the brain has an important role in the brain functioning. Insulin signalling plays a role in learning and memory, by modulating synaptic plasticity and activities of excitatory and inhibitory receptors such as glutamate and GABA receptors, and by triggering signal transduction cascades leading to alteration of gene expression that is required for long-term memory consolidation (Cardoso et al. 2009; Gasparini and Xu 2003; Zhao et al. 2004; Zhao and Alkon 2001) . Insulin/insulin receptor (IR) signalling cascade in the brain is similar to the one at the periphery.
Upon activation by insulin, IR phosphorylates different intracellular substrates, leading to the activation of two major signalling cascades; phosphoinositide 3-kinase (PI3-K) and the mitogen-activated protein kinase (MAPK) signalling pathway (Czech and Corvera 1999; Paz et al. 1996; Saltiel and Pessin 2002) . GSK-3b isoform, which is downstream the PI3-K pathway, plays a role in tau protein phosphorylation reducing its affinity for microtubules (Ishiguro et al. 1993; Hong et al. 1997) . Insulin signalling cascade can affect IDE, highly conserved Zn 2? metalloendopeptidase which also degrades Ab and insulin with a slight difference in Km (Zhao et al. 2004) .
The idea that defective insulin signalling in the brain contributes to the Alzheimer disease (AD) pathogenesis was first proposed by Siegfried Hoyer 20 years ago (Hoyer 1994) . Early abnormalities in brain glucose/energy metabolism have been found in structures with both high glucose demands and high insulin sensitivity, including those involved in cognitive function, which have suggested a role for impaired insulin signalling in the pathogenesis of sAD (Table 1) (Nitsch and Hoyer 1991; Henneberg and Hoyer 1995; Hoyer 2002 Hoyer , 2004 Lannert and Hoyer 1998) .
In line with alternation of IR signalling pathway in the human sAD brain, intracerebroventricular (icv) administration of streptozotocin (STZ) to rats (STZ-icv model) with a purpose to induce brain insulin system dysfunction has emerged as a promising experimental approach to sAD research. Streptozotocin (STZ) is a drug toxic for insulin secreting/producing cells and IR (Szkudelski 2001; Kadowaki et al. 1984) . Similar to what has been found in the human sAD brain, the glucose metabolism was found reduced in 17 of 35 brain areas in the STZ-icv-treated rats (Duelli et al. 1994 ) and the activities of glycolytic key enzymes were found markedly decreased (Plasche and Hoyer 1993) Recently, regionally specific glucose hypometabolism in FDG-PET imaging was found in monkeys 6 and 12 weeks after the STZ-icv treatment (Lee et al. 2014; Heo et al. 2011) . Numerous changes have been found in the insulin/IR signalling cascade in the brain of STZ animal model as reviewed in Table 1 . STZ-icv model has additionally been reported to develop also cerebral amyloid angiopathy in rats (appearing at 3 months and progressing up to 9 months after the STZ-icv) (Salkovic-Petrisic et al. 2006 and congophilic amyloid deposition in mice (1 month after STZ-icv) (Sodhi and Singh 2013; Wang et al. 2014) as well as increased hippocampal APP mRNA after 4 weeks in rats (de la ) and normal APP mRNA expression 5 months after STZ-icv treatment in monkeys (Lee et al. 2014; Park et al. 2013 ). All were explored in STZ-icv model mostly at one time point only, usually up to 1 or 3 months after the STZ-icv treatment in rats and mice (Agrawal et al. 2010 (Agrawal et al. , 2011 Shingo et al. 2012; Deng et al. 2009; Sodhi and Singh 2013; Wang et al. 2014; Chen et al. 2013 ) and up to 5 months in monkeys (Lee et al. 2014; Park et al. 2013; Heo et al. 2011) . Periods longer than 5 months post-STZ-icv injection have not been Cook et al. 2003 explored in regard to the brain insulin system in STZ-icv model of sAD. We aimed to investigate the time dependency in onset, development and progression of alternations in the brain insulin/IR signalling pathway in the STZ-icv rat model up to 9 months after the STZ-icv treatment.
Materials and methods

Material
The following chemicals were purchased from SigmaAldrich ( 
Animals
Three to four-month-old male Wistar rats weighing 280-330 g (Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia) were used throughout the studies. Animals were kept on standardized food pellets and water ad libitum. Rats were randomly divided into two groups (five to six per group) and given general anesthesia (ketamine 60 mg/kg/xylazine 5-10 mg/kg) followed by injection of streptozotocin (3 mg/kg) administered bilaterally into the left and right lateral ventricle according to the procedure described by Noble et al. (1967) and used in our experiments since 1990. Drug concentration and solution volume was adjusted according to the animal body weight, and a volume of 4 lL per 300 g body weight was administered (2 lL/ventricle). Control animals received bilateral icv injection of an equal volume of vehicle only. STZ-treated and respective control animals were killed 0.5, 1, 3, 6 and 9 months following the icv treatment.
For the protein and gene analyses, brains were quickly removed and cut into left and right half. The hippocampus (HPC) was cut out from the brain, immediately frozen and stored at -80°C. STZ-icv-treated animals had no symptoms of systemic diabetes and steady-state blood glucose level did not differ in comparison with control animals.
Quantitative real-time RT-PCR
Total RNA extraction Isolation of total RNA was performed using RNeasy mini kit (Qiagen GmbH, Germany) for each animal and brain region separately. An additional step was added to the original protocol to receive a pure DNA free total RNA. The total RNA was on column pre-treated with DNase-I and the original protocol was then continued to have total RNA extraction. The RNA quality and quantity was assessed using the Experion electrophoresis (BioRad Laboratories, Hercules, CA, USA) which analyses the concentration of the total RNA and quality via the ratio of the 28S/18S ribosomal RNA. Only intact total RNA samples (with at least 28S/18S ration of 1.7) were used for the gene expression analysis.
Q-PCR
To measure the gene expression profile of insulin-1 (Ins 1), IR, IDE and tau quantitative real-time RT-PCR for mRNA samples isolated from rats' hippocampus were performed. Total RNA (1-0.4 mg) from each sample was reverse transcribed with random hexamer and oligo-dT primers using iScriptTM cDNA Synthesis Kit (BioRad Laboratories; . These were normalized to the housekeeping genes: beta-actin (ACTX), ribosomal 18S (Rnr1) and glyceraldehydes-3-phosphate dehydrogenase. The housekeeping genes were tested for their stability using the geNorm program (http://www.medgen.ugent.be/*jvde somp/genorm/) (Vandesompele et al. 2002) . After analysis for the most stable housekeeping genes, a normalization factor was calculated according to the program. Absence of DNA contamination was verified by amplifying the housekeeping gene, ribosomal 18S and run on gel to observe no product. Minus RT samples were tested simultaneously with experimental samples by quantitative RT-PCR.
Western blot
Tissue preparation
Hippocampal (one animal = one sample) tissue samples from the half of the rat brain were homogenized with three Nine-month follow-up of the IR signalling 567 volumes of lysis buffer containing 10 mmol/L HEPES, 1 mmol/L EDTA, 100 mmol/L KCl, 1 % Triton X-100, pH 7.5 and protease inhibitors cocktail (1:100), and the homogenates were centrifuged at 600 g for 10 min. The supernatants were further centrifuged at 45,000 g for 30 min at 4°C, and the pellets were resuspended in 100 lL of the lysis buffer. Finally, the resuspended pellets were mixed with appropriate previous supernatants obtained after second centrifugation. Protein concentration was measured by Bradford protein assay. Samples were frozen and stored at -80°C.
Immunoblotting
Equal amounts of total protein (10 lg per sample) were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis using polyacrylamide gels and transferred to nitrocellulose membranes (Schneppenheim et al. 1991) . The nitrocellulose membranes were blocked by incubation in 5 % non-fat milk added to low salt washing buffer (LSWB) containing 10 mmol/L Tris, 150 mmol/L NaCl, pH 7.5 and 0.5 % Tween 20, 1 h at 25°C. Blocked blots were incubated overnight at 4°C with respective primary anti-total tau (1:10 000), anti-PHF-1-tau 1:300), anti-IR (1:1,000), anti-total GSK-3 a/ß (1:1,000), anti-p-GSK-3 ß (1:300), anti IDE (1:1,000) antibodies. Following the incubation, the membranes were washed three times with LSWB and incubated for 60 min at 25°C with secondary antibody solution (anti-rabbit IgG; 1:2,000 and anti-mouse IgG; 1:500). The specificity of the signal was checked on the control membranes that were not incubated with the primary antibody. After washing three times in LSWB, the membranes were immunostained using chemiluminescence Western blotting detection reagents, signal captured and visualized with the Chemi Doc BioRad (Munich, Germany) video camera system or on the film.
Statistics
The differences of gene expression and densitometric values of proteins obtained in Western blot analysis were expressed as mean ± SEM, and the significance of between-group difference was tested by Mann-Whitney U test. p \ 0.05 was considered significant.
Ethics
The experiments carried out at the University of Zagreb, Croatia, were under the guidance of the Principles of Laboratory Animal care (NIH Publication No. 86-23, revised in 1985) according to the Croatian Act on Animal Welfare (NN135; 2006) and were approved by The Ethics Committee of the Zagreb University School of Medicine (No. 04-1343 (No. 04- -2006 .
Results
Gene expression profiles
IR mRNA
A significant increase in the expression of IR mRNA in HPC was found after 2 weeks (?40 %, p \ 0.05). It started to decline afterwards demonstrating a significant decrement at 3-month (-19 %, p \ 0.05), 6-month (-26 %, p \ 0.05) and 9-month (-28 %, p \ 0.05) time point after the STZ-icv treatment in comparison to the respective control (Fig. 1) .
Ins1 mRNA
Expression of Ins1 mRNA was found unchanged 2 weeks after the STZ-icv treatment in comparison to the control but with a huge intra-group variability (Fig. 1) . Three months after the STZ-icv treatment, Ins1 mRNA was significantly downregulated (-84.5 %, p \ 0.05) and stayed decreased at 6-month (-57 %, p \ 0.05) and 9-month (-81 %, p \ 0.05) time points after the STZ-icv treatment (Fig. 1) . This was found to be the strongest effect of STZicv treatment on the insulin system in the HPC measured in our experiments during a 9-month follow-up (Fig. 1) .
IDE mRNA
The effect of STZ-icv treatment on the gene expression profile of IDE mRNA in HPC seems to be partly similar to that of insulin mRNA (Fig. 1) . Expression of IDE mRNA was insignificantly increased by 14 % compared to the control 2 weeks, after the STZ-icv treatment after which it started to decrease and became significantly decreased at 3-month (-25 %, p \ 0.05) and 6-month (-38 %, p \ 0.05) time points after the STZ-icv treatment in comparison to the control (Fig. 1) . Decrement found at 9 months (-11 %) was not significant compared to control (Fig. 1) .
Tau mRNA
Acute response seen 2 weeks after the STZ-icv treatment was demonstrated as tau mRNA upregulation (?66 %, p \ 0.05), but then this reactive increase started to fall and became normalized 3 months after the treatment (Fig. 1) . It stayed unchanged 6 and 9 months after the STZ-icv treatment, respectively, indicating the high stability of tau gene expression (Fig. 1) .
Protein expression profiles
Insulin receptor (IR)
The protein expression of IR (recognizing b-subunit of IR receptor) in HPC was found decreased 1 (-20 %, p \ 0.05), 3 (-38 %, p \ 0.05) and 6 (-28 %, p \ 0.05) months after the STZ-icv treatment in comparison to the respective control group. No change was found 9 months after STZ-icv treatment (Fig. 2) .
Insulin degrading enzyme (IDE)
The expression of IDE in HPC was found decreased after 1 month (-58 %, p \ 0.05) and stayed decreased 3 (-21 %, p \ 0.05), 6 (-26 %, p \ 0.05), and 9 (-38 % p \ 0.05) months after the STZ-icv treatment in comparison to the control, respectively (Fig. 3) .
Total and phosphorylated glycogen synthase kinase-3 beta (t-GSK-3ß and p-GSK-3ß)
The expression of t-GSK-3ß remained unchanged until 6 months but then increased 9 months after the STZ-icv treatment for 47 % (p \ 0.05) in comparison to the controls (Fig. 4) . The expression of p-GSK-3ß showed a biphasic response pattern in the course of time; acute decrease at 2 weeks (-40 %, p \ 0.05), normalization at 1 and 3 months, followed by an increase at 6 months (54 %, p \ 0.05) and then decreased 9 months (-45 %, p \ 0.05) after the STZ-icv treatment, respectively (Fig. 4) .
Total and phosphorylated tau (t-tau and p-tau) protein
The expression of t-tau in the HPC was found mildly increased at 6 months (?22 %, p \ 0.05) and decreased 9 months (-32 %, p \ 0.05) after the STZ-icv treatment in comparison to the control, respectively (Fig. 5) . The expression of p-tau in the HPC was found acutely decreased at 2 weeks (-26 %, p \ 0.05) which was followed by a significant increase at 3 and 6 months (?90 and ?25 %, p \ 0.05) time points in comparison to the control (Fig. 5) . After normalization of the phosphorylated tau levels with the level of total tau (p/t-tau ratio), significant increase in tau phosphorylation was seen 3 and 9 months after the STZ-icv treatment (Fig. 5 ). This increase in hyperphosphorylated tau appears in the course of time after the changes in insulin/IR expression.
Summary of 9-month follow-up of the protein expression of IR and IDE and of the ratio of p/t-GSK-3b and p/t-tau
While IR expression shows a slow progressive decline up to 3 months following STZ-icv treatment, after which a slow tendency of normalization of this decline has been observed towards 9-month time point (but being still significantly decreased after 6 months), IDE expression showed a biphasic pattern in the course of time (Fig. 6 ).
The acute decline in IDE expression seen after 1 month was followed by a tendency to reduce this decline which, however, remained significant at the 3-month time point. From 3 months onward, IDE expression started to slowly and progressively decline again until 9 months after STZicv treatment (Fig. 6) . The activity of GSK-3b has been measured indirectly by a ratio of phospho-to total-GSK-3b expression. The results indicated a biphasic pattern in the time course of GSK-3b activity (Fig. 6) . It was acutely increased after 2 weeks (decreased p/t-GSK-3b ratio) and then was slowly returning back to control values (1 month), and moving towards the opposite direction (decreased activity seen as increased p/t-GSK-3b ratio) until 6 months after the STZ-icv treatment (Fig. 6) . However, from 6 to 9 months, the activity of GSK-3b demonstrated a steep increase (fall in p/t-GSK-3b ratio) (Fig. 6) . Changes of tau protein phosphorylation, demonstrated as p/t-tau ratio, showed decreased tau phosphorylation up to Nine-month follow-up of the IR signalling 571 1 month, after which it started to rise and reached significantly high level at 3-month time point which was transiently normalized at 6 months but was then followed by a steep rise of tau phosphorylation 9 months after the STZicv treatment (Fig. 6) .
Discussion
In the present study we have observed alterations in the expression and phosphorylation/activation of several components of the brain insulin/IR signalling cascade but we did not find a uniform downregulation of this pathway in the course of 9 months following the STZ-icv treatment.
The changes we observed have demonstrated a kind of a biphasic time-dependent pattern in the 9-month time course which could be divided into three periods; B1 month (acute response), [1-\6 (subchronic response) and C6 months (chronic response). The results clearly show an acute response to STZ-icv application with upregulation of IR gene which is not accompanied by a change in IR protein expression as early as 2 weeks after STZ-icv administration but is rapidly followed by downregulation in expression of both IR mRNA and protein at 1-month time point, similar to what has been reported in the literature for that post-icv-treatment period (Agrawal et al. 2011; Liu et al. 2013 ). These results suggest that IR gene is affected before IR protein as acute response to the STZ-icv treatment. Since we have not measured the brain insulin level it may be only speculated that it might be altered in response to a downregulation of Ins-1 mRNA observed 1 month after STZ-icv treatment but there are no literature data on the insulin content in the brain of this model to be compared with. On the other side, insulin is a substrate of IDE and the acute response in our experiments is also seen in IDE protein level which has demonstrated a marked tendency to decline during this period which became significant at 1-month time point. These changes could be speculated to be caused by a decreased stability and/or increased degradation of IDE protein since they have not been associated with changes in IDE mRNA expression which remained unchanged in this acute phase, although we have not measured IDE activity which might be changed as well. Our data are in line with Deng et al. (2009) who have demonstrated decrement in the expression of IDE protein and its activity in HPC 3 weeks after the STZicv treatment.
Moving downstream the IR-PI-K3 signalling pathway to the GSK-3ß, an important enzyme which regulates the phosphorylation homeostasis of tau protein, our results demonstrate decreased ratio of p/t-GSK-3ß in the acute phase, indirectly indicating the abundant activation of this enzyme as early as 2 weeks after the STZ-icv treatment. Decreased p/t-GSK-3ß ratio has been reported in a period up to 1 month after the STZ-icv treatment by others as well (Deng et al. 2009; Shonesy et al. 2012) . However, in our experiments, this GSK-3b activation has not resulted in increased tau protein phosphorylation (PHF1) at this time point when decreased p/t-tau ratio was found. Also, our experiments show that this early decline in p/t-GSK-3ß ratio transiently vanishes in the course of time. It could not be excluded that decreased p/t-tau ratio in the acute phase could be due to a possible activation of protein phosphates 2A (PP2A), which is the major tau dephosphatase (Plattner et al. 2006 ) but has not been measured in our experiments or reported in STZ-icv model at this time point by others. Some support for this hypothesis might be speculated from the finding of an acutely increased PP2A activity in the hippocampus of streptozotocin-type 2 but not type 1 diabetic animals (Liao et al. 2013) , having in mind that sAD has been proposed to be a type 2 diabetes of the brain (Hoyer 1998) . It should be also kept in mind that we have used the PHF-1 antibody which targets tau protein that might be phosphorylated not only by GSK-3ß, but also by Cdk5 and ERK1/2 kinases. Selection of antibodies which target different epitopes (e.g. only Ser396 or Ser 396/404 and many other epitopes) of phospho-tau protein might also account for some inconsistency in reports of increased p-tau in cerebrum, hypothalamus and HPC (Deng et al. 2009; de la Monte et al. 2006; Lester-Coll et al. 2006; Yang et al. 2014) and unchanged p/t-tau ratio in HPC (Santos et al. 2012) found up to 1 month after STZicv treatment Although the expression of tau mRNA has been increased as early as 2 weeks after STZ-icv administration, it seems to be just a transient acute effect since it has not affected the tau protein expression and tau gene expression has not been altered in any of the time points afterwards. The work of others indicates that tau mRNA decreases 2 and 4 weeks after the treatment (de la ) which could be due to the fact that the research was done on the rat pups and because only one housekeeping gene for normalization of gene expression was used instead of three housekeeping genes used in our experiments.
In a period of 1-6 months post-icv treatment downregulation of IR and IDE and most markedly of Ins1 mRNA (3 months), respectively, has been observed. The progression of decrement in IR protein expression correlated with downregulation of the corresponding gene up to the 3-month time point after which a magnitude of decrement in the protein level started slowly but persistently to decline in the course of time. Some reports indicate downregulation of IR mRNA in HPC observed as long as 5 months after the STZ-icv treatment (Yang et al. 2014; Lee et al. 2014 ) while others (de la did not find significant changes in the HPC 4 weeks after the STZ-icv treatment. The time course of changes in IDE protein levels in our experiments did not correlate with changes in the corresponding gene as the former did not progressed but showed a tendency of diminishing the magnitude of decrement in a period from 1 to 3 months, after which a persistent decline was observed further on. The literature data indicate that IDE mRNA decreases 2 weeks after the STZicv treatment, the only time point at which IDE was investigated so far (Shingo et al. 2012) .
A tendency to return from increased to normal values has been clearly and persistently present in the GSK-3b activity in the period of 1-3 months after STZ-icv administration, ending up in the opposite direction (decreased activity) at the 6-month time point. Such a Fig. 6 The time course of changes in the protein expression of insulin receptor and insulin degrading enzyme, and in the ratio of phosphorylated to total tau protein and glycogen synthase kinase-3b, respectively, measured in the hippocampus of streptozotocinintracerebroventricularly treated rats. Protein expression was measured by Western blot analysis. Control is presented as zero line and changes of protein/ratio expression in the streptozotocin group are expressed (mean ± SEM) as percentage of control. IR insulin receptor, IDE insulin degrading enzyme, p/t-tau phospho/total tau protein, p/t-GSK-3ß phospho/total glycogen synthase kinase-3b, STZicv streptozotocin-intracerebroventricularly. *p \ 0.05 vs control measured by Mann-Whitney U test Nine-month follow-up of the IR signalling 573 change in the GSK-3b activity seems not to correlate with alterations in the IR protein level in that period (decreased expression) but since we have not measured the IR tyrosine kinase activity, it could not be excluded that it might be increased at this time point to compensate for reduced IR protein level and consequently to lead to such changes in p/t-GSK-3b ratio (activity). Additionally, it has to be kept in mind that GSK-3b phosphorylation homeostasis might be affected by different kinases besides IR-PI-3 K-Akt/ PKB pathway, like ERK which can phosphorylate GSK-3b on T48 site making GSK-3 b inactive, as regulated through IR-MAPK pathway (McCubrey et al. 2014 ). This speculation might be a possible explanation also of the tau hyperphosphorylation (PHF1) we observed in the period of 1-3 months after STZ-icv administration when GSK-3b activity was not increased. This could be because enzymes such as ERK-1/2 and Cdk-5 have also been involved in the phosphorylation of tau protein on Ser396/404 (Wen et al. 2008; Takahashi et al. 2000; Ferrer et al. 2001) . The literature data on ERK -1/2 level/activity in the brain of an STZ-icv model show insignificant increment of ERK1/2 activity in HPC (Agrawal et al. 2011 ) and significant decrement in phosphorylation of ERK while there is no research on the Cdk-5 in the brain of STZicv model. Our preliminary experiments showed increased p-ERK expression measured at 1 and 9 months after STZicv treatment (unpublished data). Also, increased Cdk-5 expression and increased ERK-1/2 phosphorylation have been found in human sAD postmortem (Takahashi et al. 2000; Ferrer et al. 2001) . Finally, the last part of the post-STZ-icv observational period in our research (6-9 months), clearly demonstrates that contrary to the no further progression in downregulation of genes explored (IR, Ins-1, IDE) from the previously observed level, alterations in protein expression or enzyme activity downstream the IR/PI-3 K signalling pathway generally worsen; IDE level continue to decline, GSK-3b activity increases and tau hyperphosphorylation rises. The level of IR protein has been the only one which has returned to the control values after 9 months for unknown reason but since we have not measured the tyrosine activity of IR, it could not be excluded that on a long term, in spite of normalized IR level, its tyrosine activity might be decreased leading to downstream cascade dysfunction.
To conclude, our results provide evidence that the changes in the IR signalling cascade downstream the PI-3 K pathway depend on the time past after the STZ-icv administration. The acute changes seem to be partly reversible up to 3-6 months while chronic and progressive changes are particularly manifested in a period longer than 6 months after STZ-icv administration. Interestingly, such a biphasic time pattern in brain insulin/IR signalling cascade correlates well with the cognitive deficits we have observed in a 9-month follow-up of STZ-icv-treated rats (manuscript in preparation). Therefore, it could be hypothesized that the acute changes might reflect the nonspecific toxicity of STZ (known as cytotoxic agent) while the chronic changes seem to correlate more with corresponding ones observed in human sAD brain, which particularly might be true for the tau and amyloid pathology development and progression. Awareness of such a difference in a time course of changes in the brain insulin system in STZ-icv model of sAD might be of utmost importance in translational sAD research. Both acute and chronic STZ-icv-induced changes might represent a valuable tool, the former to explore the possible etiopathogenesis of sAD and mechanisms of its prevention, and the latter to assess novel approaches in the disease modifying therapy of sAD, and should, therefore, be exploited accordingly.
